BACKGROUND There are limited markers that could facilitate individualized tacrolimus treatment in the early posttransplantation period. Genetic factors have been found to play critical roles in determining tacrolimus pharmacokinetics. OBJECTIVE We aimed to examine the association of donor and recipient Toll-like receptor (TLR) polymorphisms with tacrolimus elimination and the potential mechanism for TLR gene polymorphismmediated tacrolimus metabolism. METHODS Two independent cohorts including 297 patients receiving liver transplantation (LT) were enrolled in this study (cohort A was composed of 200 patients; cohort B included 97 patients and served as a validation set). Toll-like receptors polymorphisms were genotyped using TaqMan single nucleotide polymorphisms (SNPs) assays. The protein expressions were detected by Western blotting. The metabolism assay was used to quantify tacrolimus elimination. The activity of nuclear factor-kB (NF-kB) was evaluated by luciferase reporter assay. RESULTS Tacrolimus dose-adjusted trough blood concentrations (C/D) ratios were significantly lower for donor TLR9 rs352139 AG/GG carriers than AA carriers at weeks 1, 2, and 3 after LT. In multivariate analysis, donor and recipient CYP3A5 rs776746 and donor TLR9 rs352139 were independent predictors of tacrolimus C/D ratios in the early period after transplantation in both cohorts. When investigating the combined effects of donor CYP3A5 rs776746 and donor TLR9 rs352139 genotypes, the C/D ratios were remarkably significant at all time points during the first month after LT within the four groups. Furthermore, CYP3A5 mRNA expression in liver tissue was significantly higher for AG/GG patients than AA carriers after LT. In addition, we demonstrated that the TLR9 rs352139 genetic variant promotes tacrolimus metabolism of liver cells via upregulation of CYP3A5, which is dependent on the repression of NF-jB/pregnane X receptor (PXR) signaling. CONCLUSIONS Donor TLR9 rs352139 genetic variant facilitated tacrolimus elimination during the early stage after LT in Chinese patients, which might be related to the upregulation of CYP3A5 enzyme via the NF-kB/PXR signaling pathway. KEY WORDS CYP3A5, liver transplantation, SNP, TLR9, tacrolimus metabolism.
Liver transplantation (LT) is the preferred treatment option for most patients with endstage liver disease. The use of immunosuppressive regimens has significantly improved the clinical outcome of liver transplant recipients. Tacrolimus, as a calcineurin inhibitor, has been widely used to prevent allograft rejection and improve patient survival. 1 However, tacrolimusbased therapy could be complicated by its narrow therapeutic index and broad interindividual variability. 2, 3 Insufficient immunosuppressive therapy can cause graft rejection, whereas excessive immunosuppression often leads to metabolic complications, such as hypertension, obesity, and diabetes mellitus. 4 Therefore, it is urgent to identify markers that could facilitate individualized tacrolimus treatment in the early posttransplantation period.
Genetic factors have been found to play critical roles in determining tacrolimus pharmacokinetics. Cytochrome P450 3A5 (CYP3A5), a member of the cytochrome P450 3A subfamily, is known to mediate metabolism and systemic clearance of tacrolimus. 5 The single nucleotide polymorphisms (SNP) within intron 3 of CYP3A5 (6986A>G, rs776746) result in the absence of enzymatic activity, which significantly influences the pharmacokinetics of tacrolimus. 6, 7 Indeed, many reports suggest that CYP3A5 rs776746 GG genotype carriers (nonexpressers) exhibit higher dose-adjusted tacrolimus exposure and a lower dose requirement than in recipients with the AA or AG genotype (expressers). [8] [9] [10] [11] [12] However, individual variability in tacrolimus elimination still remains incompletely explained.
Toll-like receptors (TLRs) are pathogen recognition receptors that possess a fundamental role in orchestrating the innate (and subsequently adaptive) immune responses. 13 Currently, 10 functional TLRs (TLR1 to TLR10) have been identified in human beings.
14 TLRs can be triggered by exogenous ligands present on invading pathogens as well as endogenous ligands. 15 TLRs are not only widely expressed by cells of the immune system but also within the liver cell populations, thereby bestowing these cells with a critical function in LT. 16 It has been demonstrated that TLR signaling plays a crucial role in many facets of transplantation biology, including allograft rejection, ischemia-reperfusion injury, and inflammatory injury. 17 Recent evidence also suggests that activation of TLR pathways influence the expressions of hepatic drug-metabolizing enzymes and transporters. 18 Owing to the fact that TLR levels were readily affected by its SNPs, it could be speculated that TLR genetic variants might correlate with drug clearance in LT patients.
In this study, we comprehensively examined the TLR genotypes of liver transplant donors and recipients to clarify the influence of these genetic variants on tacrolimus dose requirements and pharmacokinetics after transplantation. We found that TLR9 rs352139 polymorphism contributed to differences of tacrolimus elimination in patients at an early time period after LT. The potential mechanism responsible for TLR gene polymorphism-mediated tacrolimus metabolism was also investigated.
Materials and Methods

Patients and Study Design
Two independent cohorts including 297 patients receiving orthotopic LT between January 2012 and December 2016 were enrolled. 19 Cohort A comprised patients recruited from Shanghai General Hospital of Shanghai Jiao Tong University (n = 115) and the First Affiliated Hospital of Zhengzhou University (n = 85). Cohort B (validation set) comprised 97 patients from the First Affiliated Hospital, Zhejiang University School of Medicine. Cohort B was used to validate the novel findings obtained from cohort A. Recruiting criteria included (i) patients aged 18 years or older, (ii) deceased donor primary transplantation, and (iii) patients receiving tacrolimus-based immunosuppressive therapy. Exclusion criteria were (i) multiorgan transplant patients, (ii) follow-up time of no more than 1 month, and (iii) incomplete patient medical records. The patient characteristics were previously described. 19 An initial dosage of tacrolimus (0.06 mg/kg/day) was administered orally twice daily. Therapeutic drug monitoring was performed routinely after LT.
Ethics Statement
The research was approved by the Ethics Committee of Shanghai General Hospital of Shanghai Jiao Tong University, the First Affiliated Hospital of Zhengzhou University, and the First Affiliated Hospital of Zhejiang University. This study was conducted in accordance with the Declaration of Helsinki and its amendments.
Data Collection
Blood samples for routine tacrolimus monitoring were collected before the morning administration. Whole blood tacrolimus concentrations were detected by Pro-TracIITMFK506 ELISA kit (Diasorin, Saluggia, Italy) with microparticle enzyme immunoassay (ELx 800NB analyzer, BioTek, Winooski, VT). Dose-adjusted trough blood concentrations (C/D ratios) were quantified with trough concentration and weight standardized 24-hour tacrolimus dose (mg/kg/day). Clinical parameters such as hemoglobin (Hb, g/L), albu-
, and urea (mmol/L) were also included in this study.
Genomic DNA Isolation and Genotyping
Genomic DNA was isolated from the previously stored donor and recipient liver tissue using an AllPrep DNA/RNA mini-kit (Qiagen, Hilden, Germany). Genotyping of SNPs was performed using the Sequenom MassARRAY SNP platform (Sequenom, San Diego). The protocols of this assay included polymerase chain reaction (PCR) amplification, shrimp alkaline phosphatase treatment, primer extension, resin cleanup, spotting of products on a SpectroCHIP, and detection by mass spectrometry. The sequencing primers for SNPs are displayed in Table S1 .
Reagents, Cell Culture, and Transfection
The HEK293 cells and the human hepatic cell line HuH-7 were purchased from Novobio Scientific (Shanghai, China). These cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum at 37°C in 5% CO 2 . The siRNA targeting CYP3A5 mRNA was purchased from Genepharma (Shanghai). Transfection was performed using Lipofectamine 3000 according to the manufacturer's instructions. After 6 hours, the medium was changed to normal medium and cells were cultured for a further 48 hours. TPCA-1 and RIF were purchased from Selleckchem (Houston) and were used in accordance with manufacturer's instructions.
Tacrolimus Metabolism Assay
The tacrolimus metabolism assay was performed as previously described. 20 Cells were grown to confluence for 3 weeks in collagen I-coated plates and then layered with Corning Matrigel matrix. Next, cells were induced with rifampicin (10 lmol/L) and phenytoin (100 lmol/L) for 3 days. On the fourth day, tacrolimus was added and its final concentration reached 13 ng/mL. Cells were cultured overnight, and media were collected. Metabolites were detected by liquid chromatography-mass spectrometry.
Dual-Luciferase Reporter Assay
The HEK293 cells were cotransfected with dual-luciferase reporters (nuclear factor jB [NFjB] reporter and the Renilla luciferase reporter) and either control vector (empty pGL3 vector) or the TLR9 expression vectors (pGL3-TLR9; pGL3-TLR9-mutant: rs352139). The cells were then treated with and without proinflammatory cytokine tumor necrosis factor a (TNF-a, 5 ng/ mL, R&D systems, Minnesota) for 24 hours. The cells were then collected and luciferase activity was examined using the Dual Luciferase Assay (Promega, Wisconsin).
RNA Isolation and qRT-PCR Analysis
Total RNAs were extracted using Trizol Reagent (Invitrogen, Massachusetts) according to the manufacturer's protocol and were reversetranscribed using the reverse transcription kit (Invitrogen, USA). All samples were quantified by the comparative Ct method for relative gene expression and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the control. The sequencing primers were as follows:
Western Blotting
Western blotting analysis was performed as previously described. 21 Cell lysates were prepared with the RIPA lysis buffer containing protease inhibitors. Equal amounts of total proteins were subjected into sodium dodecyl sulfatepolyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes (Millipore, Massachusetts). Membranes were incubated with antibodies specific for CYP3A5 (1:500, ab108624, Abcam, Cambridge, UK) followed by horseradish peroxidase-conjugated secondary antibody. Finally, the membranes were visualized using chemiluminescence detection.
Statistical Analysis
Demographic and clinical data are shown as mean AE standard deviation (SD). KolmogoroSmirnov test was used to confirm the normal distribution of log-transformed tacrolimus C/D ratios. Quantitative data between two groups were compared by using the Student t test or MannWhitney U test, and among several groups by Kruskal-Wallis. Hardy-Weinberg equilibrium and the allele frequency were analyzed with the use of SHEsis software. 22 Multivariable linear regression was applied to evaluate the influence of the CYP3A5 rs776746 polymorphism and TLR9 rs352139 polymorphism as well as other clinical characteristics (Hb, ALT, AST, TBIL, DBIL, Alb, Cr, urea) on the tacrolimus C/D ratios. Statistical analysis was performed with SPSS version 19.0, and two-tailed p<0.05 was considered statistically significant.
Results
Effects of TLR Polymorphisms on Tacrolimus C/ D Ratios (Cohort A)
Among the myriads of SNPs listed in the database provided by the National Center for Biotechnology Information (NCBI), we tried to study SNPs that have been reported to influence certain TLR expressions. [23] [24] [25] [26] [27] [28] [29] [30] The investigated SNPs were all in Hardy-Weinberg equilibrium. No differences in genotype frequencies of TLR between donors and recipients were found ( Table 1 ). The effect of TLR genetic variants on tacrolimus C/D ratios at different times posttransplantation was individually explored. Heterozygous and homozygous variants of TLRs were grouped and analyzed against the patients homozygous for the wildtype. Interestingly, tacrolimus C/D ratios of donor TLR4 rs1927907 GG carriers were significantly higher than those of AA/AG carriers at weeks 1 and 4 (p=0.010, p=0.029, respectively, Table 2 ). Moreover, the donor TLR9 rs352139 AG/GG Table 2 ). No statistically significant association was observed in other types of SNPs at all time points (data not shown). The role of TLR4 rs1927907 in tacrolimus pharmacokinetics after LT has been investigated in our previous study; 27 thus, we mainly evaluated the influence of TLR9 rs352139 on tacrolimus elimination in the setting of LT, using both cohorts A and B.
Multivariate Analysis for Factors Affecting Tacrolimus Pharmacokinetics (Cohort A)
Next, we examined the relationship between the influence factors and tacrolimus pharmacokinetics in the first month following LT using multiple linear regression models (cohort A). The incorporated cofactors were comprised of donor and recipient CYP3A5 rs776746 genotypes, TLR9 rs352139 genotype, Hb, ALT, AST, TBIL, DBIL, Alb, Cr, and urea. Consistent with previous findings, 19 tacrolimus C/D ratios were significantly predicted by donor and recipient CYP3A5 rs776746 genotypes at every week. Notably, donor TLR9 rs352139 polymorphism was also identified as an independent predictor of C/D ratios for weeks 1, 2, and 3 (Table 3) .
Results from the Cohort B (Validating Set)
To further confirm the potential role of TLR9 rs352139, a second cohort of 97 patients who underwent the same LT treatment was evaluated. No differences in genotype frequencies of rs352139 between donors and recipients were observed (Table 1) . When tacrolimus C/D ratios at different time periods posttransplantation were compared among patients of this cohort, donor TLR9 rs352139 AG or GG were associated with lower tacrolimus C/D ratios at weeks 1 and 2 ( Figure 1) . Furthermore, multivariate linear regression analysis of this validating cohort confirmed that besides the consistent roles of daily dose and CYP3A5 rs776746 genotypes, TLR9 rs352139 polymorphism was an independent predictor of C/D ratios for week 1 (Table 4) .
Combined Effects of CYP3A5 rs776746 and TLR9 rs352139 on Tacrolimus C/D Ratios
The effects of donor CYP3A5 rs776746 and donor rs352139 genotypes were then investigated in combination. Group 1 consisted of . Among these four groups, tacrolimus C/D ratios were significantly different at all measurement time points during the first month posttransplantation (group 1 < group 2 < group 3 < group 4, Table 5 ). Taken together, genotype classification exhibits a better predictive ability of tacrolimus C/D ratios than donor CYP3A5 genotype alone.
CYP3A5 mRNA Expression in TLR9 rs352139 AA or AG/GG Carriers Our explorations revealed that tacrolimus C/D ratios were significantly lower for patients with donor AG/GG genotype than those with AA genotype in the early period after LT. This prompted us to test whether CYP3A5 mRNA expression was different between these two groups among CYP3A5 expressers. We collected liver samples before (AA: n = 10; AG/GG: n = 10) and after LT (AA: n = 5; AG/GG: n = 5) through biopsy. Interestingly, CYP3A5 mRNA expression was significantly higher for AG/GG patients than AA patients after LT (Figure 2B) , whereas the difference between the two groups was not found before LT (Figure 2A ).
TLR9 rs352139 Promotes Tacrolimus Metabolism of Liver Cells via Upregulation of CYP3A5
To further elucidate the effect of TLR9 rs352139 polymorphisms on tacrolimus elimination, the metabolism assay was performed using human liver cell line HuH-7. First, HuH-7 cells were transfected with blank plasmids or TLR9 expression plasmids (pGL3-TLR9; pGL3-TLR9-mutant: rs352139). Compared with wild-type TLR9 vector, the rs352139 genetic variant remarkably decreased TLR9 expression (Figure 3A) , which is consistent with previously reported findings. 30 Moreover, the pGL3-TLR9-mutant cells had lower levels of tacrolimus after overnight incubations than pGL3-TLR9 cell lines because of the enhanced metabolism (Figure 3B) . It is well known that TLR9 can initiate inflammatory responses by activating the NF-jB signaling pathway. 31 Considering NF-jB could regulate pregnane X receptor (PXR)-mediated CYP3A expression, 32, 33 we speculated that the rs352139 genetic variant might affect tacrolimus metabolism by regulating CYP3A5 in liver cells. Indeed, CYP3A5 expression was significantly increased in cells transfected with pGL3-TLR9-mutant ( Figure 3A) . When siRNA was used to downregulate CYP3A5 levels ( Figure 3C ), the accelerated tacrolimus elimination of the pGL3-TLR9-mutant cells was also reversed (Figure 3D) . Taken together, TLR9 rs352139 Figure 1 . Effect of donor Toll-like receptor 9 polymorphism (rs352139) on tacrolimus concentration/dose ratio in liver transplant patients in weeks 1, 2, 3, and 4 after transplantation. ***p<0.001.
promotes tacrolimus metabolism of liver cells via upregulation of CYP3A5 expression.
TLR9 rs352139-Mediated Upregulation of CYP3A5 Depends on NF-jB/PXR Signaling
We then investigated whether NF-jB/PXR signaling was involved in the function of TLR9 rs352139 genetic variant. As expected, a significantly decreased expression of p-p65 as well as PXR in pGL3-TLR9-mutant cells was observed ( Figure 4A ). In addition, luciferase reporter assay also showed that HEK293 cells cotransfected with pGL3-TLR9 was 1.56 times higher than that in cells cotransfected with pGL3-TLR9-mutant regarding luciferase activity (Figure 4B ). After stimulation with TNF-a, the reporter activity of pGL3-TLR9 cells was 2.89 times higher than that in cells cotransfected with pGL3-TLR9-mutant ( Figure 4C ). When incubating cells with TPCA-1 (NF-jB activity inhibitor), CYP3A5 protein expressions and tacrolimus metabolism of liver cells were remarkably increased. Conversely, RIF (PXR agonist) treated cells exhibited decreased CYP3A5 levels and lower tacrolimus elimination ( Figure 4D ). Therefore, TLR9 rs352139 variant upregulates CYP3A5 expression to promote tacrolimus metabolism of hepatocytes via NF-jB/PXR signaling.
Discussion
Tacrolimus is recognized as the backbone of immunosuppressive therapy after LT, even though it exhibits marked toxicity and remarkable interindividual pharmacokinetic variability. During the last decade, many genetic polymorphisms have been identified to influence tacrolimus elimination, but only CYP3A5 rs776746 polymorphisms are generally accepted. 8 These studies mainly concentrated on the enzymes and transporters involved in drug metabolism, which may not fully elucidate the differences in tacrolimus pharmacokinetics between individual patients. Therefore, we aimed to investigate additional markers involved in the variability seen with tacrolimus clearance.
As a conserved family of pattern recognition receptors, TLRs are expressed in many kinds of liver cells and play a critical role in LT. Currently, we comprehensively explored the association between the TLR polymorphisms and tacrolimus pharmacokinetics in the setting of LT. The results showed that both TLR4 rs1927907 and TLR9 rs352139 genotypes were identified to affect tacrolimus elimination, and the function of the latter was further dissected. As for rs352139 polymorphisms, tacrolimus C/D ratios were significantly higher for donor AA carriers than those with the G allele at weeks 1, 2, and 3. The differences between the two groups were not found at late time periods. Moreover, donor TLR9 rs352139 genotype independently predicts tacrolimus C/D ratios in the early stage after LT in both the training set (cohort A) and validating set (cohort B). Additionally, using the metabolism assay, we observed that rs352139 genetic variant promotes tacrolimus clearance in human liver cell line Huh-7. These findings suggest that TLR9 rs352139 All data were shown as means AE standard deviation.
polymorphism plays a key role in tacrolimus metabolism in the early posttransplantation period. It has been elucidated that during the early posttransplantation period, liver allografts are subjected to ischemia-reperfusion injury and inflammatory reaction. These responses can exert profound influences on the expression and activity of hepatic CYP3A enzymes. 34, 35 In this study, CYP3A5 mRNA expression in liver tissues was significantly higher for donor AG/GG patients than AA carriers after LT. Furthermore, the results showed that donor TLR9 rs352139 genetic variant improved the CYP3A5 expression through the NF-jB/PXR signaling pathway. Indeed, previous evidence has suggested that the function of TLR9 is largely associated with the NF-jB signaling. 36 Inflammation-induced NF-jB activation can repress PXR expression, thereby downregulating drug-metabolizing enzymes CYP3A. 32 Finally, we revealed that targeting CYP3A5 expression could abolish the effect of rs352139 genotype on tacrolimus elimination in HuH-7 cells. Therefore, this research demonstrates an important function of TLR9 rs352139 polymorphism in drug metabolism of liver cells. The CYP3A5 rs776746 polymorphism remained the underlying factor explaining the interindividual variation of tacrolimus clearance, which has been confirmed in our cohort previously. 19 Of note, combined donor CYP3A5 rs776746 and donor TLR9 rs352139 genotypes showed an increased significance of the observed effects on pharmacokinetics compared with CYP3A5 genotype alone. Tacrolimus C/D ratios were influenced significantly by the TLR9 and CYP3A5 combined genotype. The poor metabolizers had the highest C/D ratio at all time points, suggesting they need lower drug doses to achieve a target blood concentration in the early stage after LT. Hence, combining the TLR9 and CYP3A5 polymorphisms might produce a better prediction of the optimal tacrolimus starting dose.
However, several limitations must be acknowledged in this study. First, the populations included in this research were exclusively Han Chinese; thus, further investigations are needed to confirm this finding in other ethnic groups. It is quite possible that different genetic backgrounds may lead to controversial results. Second, we only explored those polymorphisms that influenced the expressions of certain TLRs, and other genetic variants of TLRs are likely to affect tacrolimus elimination in patients after LT.
Conclusion
In summary, our results demonstrate that TLR9 rs352139 A>G polymorphism in donors contribute to differences in the C/D ratios of tacrolimus in patients during the early time period after LT. This effect may be correlated with the upregulation of CYP3A5 enzyme through the NF-jB/PXR signaling pathway. Combined donor CYP3A5 rs776746 and donor TLR9 rs352139 genotypes could improve the predictive ability of tacrolimus C/D ratios. These findings may help individualize tacrolimus administration in liver transplant recipients. 
